Samjin Pharmaceutical announced Monday that it has been selected for the "World Class Plus Project," a government support program overseen by the Ministry of Trade, Industry and Energy (MOTIE).
The project aims to nurture companies with global growth potential and competitiveness in advanced industries including bio, semiconductors, and artificial intelligence (AI). Selected companies receive support in research and development (R&D), exports, financing, and consulting.
Samjin Pharmaceutical, named as a leading company in the advanced bio sector, received high marks for its project on "advancing innovative new drugs and developing platform technologies for formulations and antibody-drug conjugates (ADCs)." The selection signals government recognition of the commercial viability and global market potential of Samjin's core pipeline — the immune and inflammatory disease treatment SJN314 and its ADC platform.
Backed by government support, Samjin Pharmaceutical plans to pursue global commercialization in earnest, centered on three growth engines: △expanding indications for SJN314, △building a full-cycle ADC platform, and △advancing a next-generation controlled-release formulation platform.